Cargando…

IL4-STAT6 signaling induces CD20 in chronic lymphocytic leukemia and this axis is repressed by PI3K(δ) inhibitor idelalisib

Detalles Bibliográficos
Autores principales:	Sandova, Veronika, Pavlasova, Gabriela Mladonicka, Seda, Vaclav, Cerna, Katerina Amruz, Sharma, Sonali, Palusova, Veronika, Brychtova, Yvona, Pospisilova, Sarka, Fernandes, Stacey M., Panovska, Anna, Doubek, Michael, Davids, Matthew S., Brown, Jennifer R., Mayer, Jiri, Mraz, Marek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2021
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8561290/ https://www.ncbi.nlm.nih.gov/pubmed/34196167 http://dx.doi.org/10.3324/haematol.2021.278644

Ejemplares similares

Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia
por: Kminkova, Jana, et al.
Publicado: (2014)

MicroRNA Profiling of Self-Renewing Human Neural Stem Cells Reveals Novel Sets of Differentially Expressed microRNAs During Neural Differentiation In Vitro
por: Fedorova, Veronika, et al.
Publicado: (2023)

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
por: Olbertova, Helena, et al.
Publicado: (2022)

Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of WNT5A promoter and undetectable expression of WNT5A gene
por: Poppova, Lucie, et al.
Publicado: (2022)

Low-burden TP53 mutations in CLL: clinical impact and clonal evolution within the context of different treatment options
por: Malcikova, Jitka, et al.
Publicado: (2021)

The regulation and function of CD20: an “enigma” of B-cell biology and targeted therapy
por: Pavlasova, Gabriela, et al.
Publicado: (2020)

Structural, Biochemical, and Biophysical Characterization of Idelalisib Binding to Phosphoinositide 3-Kinase δ
por: Somoza, John R., et al.
Publicado: (2015)

Glioblastoma and cerebral organoids: development and analysis of an in vitro model for glioblastoma migration
por: Fedorova, Veronika, et al.
Publicado: (2023)

Novel CHK1 inhibitor MU380 exhibits significant single-agent activity in TP53-mutated chronic lymphocytic leukemia cells
por: Boudny, Miroslav, et al.
Publicado: (2019)

S142: FOXO1-RICTOR AXIS INDUCES ADAPTIVE INCREASE IN AKT ACTIVITY DURING BCR INHIBITOR THERAPY IN CLL: IMPLICATIONS FOR COMBINATION THERAPY
por: Ondrisova, Laura, et al.
Publicado: (2023)

The PI3Kδ inhibitor idelalisib impairs the function of human dendritic cells
por: Braun, Christiane, et al.
Publicado: (2021)

The PI3Kδ Inhibitor Idelalisib Diminishes Platelet Function and Shows Antithrombotic Potential
por: Barrachina, María N., et al.
Publicado: (2021)

The PI3Kδ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL
por: Adam, Etai, et al.
Publicado: (2017)

Idelalisib for the Treatment of Chronic Lymphocytic Leukemia
por: Khan, Maliha, et al.
Publicado: (2014)

Idelalisib: a rare cause of enterocolitis
por: Balagoni, Harika, et al.
Publicado: (2016)

PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors
por: Yahiaoui, Anella, et al.
Publicado: (2017)

P602: SINGLE-CELL RNA-SEQUENCING ENABLES TRACKING AND CHARACTERIZATION OF RARE CLL CELLS WITH THE POTENTIAL TO CAUSE REFRACTORINESS.
por: Kurucová, Terézia, et al.
Publicado: (2023)

Bioinformatic strategies for the analysis of genomic aberrations detected by targeted NGS panels with clinical application
por: Hynst, Jakub, et al.
Publicado: (2021)

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo
por: Palazzo, Adam, et al.
Publicado: (2018)

Crystal structure of idelalisib tert-butanol monosolvate dihydrate
por: Nerdinger, Sven, et al.
Publicado: (2019)

Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage
por: Mancikova, Veronika, et al.
Publicado: (2022)

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
por: Malcikova, J, et al.
Publicado: (2015)

Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia
por: Sharman, Jeff P., et al.
Publicado: (2019)

Idelalisib impairs TREM-1 mediated neutrophil inflammatory responses
por: Alflen, Astrid, et al.
Publicado: (2018)

Rapid and complete response to idelalisib in a case of Richter syndrome
por: Bagacean, Cristina, et al.
Publicado: (2019)

Idelalisib induces PUMA-dependent apoptosis in colon cancer cells
por: Yang, Shida, et al.
Publicado: (2016)

Idelalisib may have the potential to increase radiotherapy side effects
por: Gryc, Thomas, et al.
Publicado: (2017)

Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia
por: Kost, Sara E. F., et al.
Publicado: (2019)

A novel strategy for the manufacture of idelalisib: controlling the formation of an enantiomer
por: Mekala, Nagaraju, et al.
Publicado: (2018)

An unusual case of Idelalisib‐related pneumonitis with severe respiratory failure
por: Sousa, Domingos, et al.
Publicado: (2020)

RNA-seq Characterization of Melanoma Phenotype Switch in 3D Collagen after p38 MAPK Inhibitor Treatment
por: Čermák, Vladimír, et al.
Publicado: (2021)

Management of adverse events associated with idelalisib treatment: expert panel opinion
por: Coutré, Steven E., et al.
Publicado: (2015)

Idelalisib: Practical Tools for Identifying and Managing Adverse Events in Clinical Practice
por: Driscoll, Nancy
Publicado: (2016)

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach
por: de Weerdt, Iris, et al.
Publicado: (2017)

Disseminated cryptococcal disease during treatment with idelalisib and corticosteroids for follicular lymphoma
por: Hengeveld, Paul J, et al.
Publicado: (2020)

Keratin 36, a specific marker of tongue filiform papillae, is downregulated in squamous cell carcinoma of the mobile tongue
por: Brychtova, Veronika, et al.
Publicado: (2020)

Novel genetic variant of HPS1 gene in Hermansky-Pudlak syndrome with fulminant progression of pulmonary fibrosis: a case report
por: Doubková, Martina, et al.
Publicado: (2019)

RGDS-Modified Superporous Poly(2-Hydroxyethyl Methacrylate)-Based Scaffolds as 3D In Vitro Leukemia Model
por: Svozilová, Hana, et al.
Publicado: (2021)

p53 limits B cell receptor (BCR) signalling: a new role for miR-34a and FOXP1
por: Cerna, Katerina, et al.
Publicado: (2018)

CD20 is dispensable for B-cell receptor signaling but is required for proper actin polymerization, adhesion and migration of malignant B cells
por: Kozlova, Veronika, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_lrgfbiibr5qe34ldq4eaducunm